← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Marker Therapeutics, Inc.
Houston, TX
$7,900,411
Total funding
5
Grants
Funding over time
peak $3.5M · FY2022–25$5M$3.8M$2.5M$1.3M$0
'22
'23
'24
'25
Funding mix
By agency
NIH$6,672,209 · 4
FDA$1,228,202 · 1
By mechanism
R44$6,672,209 · 4
R01$1,228,202 · 1
Investigators at Marker Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy$1,348,474
R44 · FY2025 · CA
A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX$674,275
R44 · FY2024 · CA
A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX$674,275
R44 · FY2025 · CA
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma$665,000
R44 · FY2025 · CA
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma$665,000
R44 · FY2024 · CA
Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant$664,838
R44 · FY2023 · CA
Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant$664,838
R44 · FY2024 · CA
Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant$664,838
R44 · FY2025 · CA
Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy$650,671
R44 · FY2024 · CA
Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease$519,750
R01 · FY2024 · FD
Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease$519,750
R01 · FY2022 · FD
Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in AML Patients following Allogeneic Stem Cell Transplant with Minimal Residual Disease$188,702
R01 · FY2025 · FD